“2017 was a year of strong progress for Valeant as we delivered organic growth2 across nearly 75 percent of the Company while significantly reducing our debt and investing in our Bausch + Lomb, Salix and Ortho Dermatologics businesses,” said Joseph C. Papa, chairman and CEO, Valeant.
February 28, 2018
· 96 min read